rs290475 — TCF7L2 TCF7L2 Beta Cell Function Depth Variant

A Third Window Into TCF7L2 — the Wnt Gateway for Blood Sugar

The TCF7L2 gene holds a unique distinction in human genetics: it is the single strongest common genetic predictor of type 2 diabetes, with effects replicated across every major ethnic population studied. Two variants — rs7903146 and rs12255372 — are already well-characterized in this encyclopedia. rs290475 sits ~26,000 base pairs upstream of their coding region in intron 4, potentially tagging a distinct functional haplotype within the same gene-regulatory landscape.

The Mechanism

TCF7L2 encodes a [transcription factor | a protein that controls which genes are switched on or off by binding to specific DNA sequences] in the canonical Wnt/beta-catenin signaling pathway¹¹ Wnt/beta-catenin signaling pathway
a fundamental cell-communication cascade governing development, stem cell maintenance, and metabolic homeostasis. In the pancreatic beta cell, TCF7L2 does two critical jobs: it drives expression of the GLP-1 receptor²² GLP-1 receptor
the receptor for GLP-1, a gut hormone that potently stimulates insulin secretion after meals and regulates the beta-cell's survival via the p53 pathway. Beta cell-specific TCF7L2 knockout in mice³³ Beta cell-specific TCF7L2 knockout in mice
Mitchell et al. Selective disruption of Tcf7l2 in the pancreatic β cell impairs secretory function and lowers β cell mass. Hum Mol Genet, 2015 reduces GLP-1 receptor expression by ~40% and impairs both glucose-stimulated and GLP-1-stimulated insulin secretion.

In the liver, TCF7L2 plays an opposing but complementary role. Insulin normally upregulates hepatic TCF7L2 expression, which then acts as a brake on gluconeogenesis⁴⁴ gluconeogenesis
the liver's ability to manufacture new glucose from non-sugar precursors such as amino acids and glycerol. Knocking out hepatic TCF7L2⁵⁵ Knocking out hepatic TCF7L2
Ip et al. AJP Endocrinol Metab, 2012 increases glucose output, while overexpression dampens it — evidence that TCF7L2 is a direct molecular link between the Wnt pathway and fasting blood sugar.

The deep intronic position of rs290475 (c.484-26924 in the major transcript) suggests it acts as a regulatory tag — influencing nearby transcription factor binding sites, chromatin accessibility, or splice-site efficiency rather than altering the protein sequence. Intronic variants in this region of TCF7L2 have been shown to alter islet-specific enhancer activity, and rs290475 may mark a distinct regulatory element not captured by rs7903146.

The Evidence

rs290475 has no direct type 2 diabetes GWAS entry in the GWAS Catalog as of 2026. Its most prominent documented associations — identified via proxy analysis — are with bipolar disorder in the context of elevated BMI⁶⁶ bipolar disorder in the context of elevated BMI
Winham et al. Genome-wide association study of bipolar disorder accounting for effect of body mass index identifies a new risk allele in TCF7L2. Mol Psychiatry, 2014 and with neuroticism conditioned on educational/cognitive phenotypes. This is a hallmark of pleiotropic TCF7L2 variants — the Wnt pathway governs both metabolic and neurodevelopmental programs, and intronic regulatory variants can produce tissue-specific expression effects that manifest differently in brain versus pancreas versus liver.

The broader TCF7L2 locus literature documents the mechanism clearly: risk allele carriers show impaired incretin-mediated insulin secretion⁷⁷ risk allele carriers show impaired incretin-mediated insulin secretion
Florez et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. NEJM, 2006, reduced beta cell mass, and increased hepatic glucose output. A global meta-analysis of 17,000+ T2D cases⁸⁸ global meta-analysis of 17,000+ T2D cases
Cauchi et al. J Mol Med, 2007 established the TCF7L2 locus OR of 1.46 — the largest effect size for any common T2D variant. Because rs290475 tags this same regulatory region, its C-allele carriers may share a portion of that risk through a haplotype distinct from the primary rs7903146 signal, but direct confirmation awaits fine-mapping studies with phenotyped T2D cohorts.

Practical Actions

The evidence for rs290475-specific dietary guidance is indirect, extrapolated from the broader TCF7L2 locus and GLP-1/hepatic mechanism. If you carry the C allele, the most relevant actions target:

1. Incretin optimization — meals and foods that stimulate GLP-1 secretion most effectively (high-fiber, low-glycemic-index foods; legumes; fermented dairy) support the impaired GLP-1 signaling pathway.
2. Hepatic glucose management — spreading carbohydrate intake across multiple smaller meals reduces peak gluconeogenic stimulus and leverages the meal-responsive TCF7L2/Wnt axis in the liver.
3. Metabolic monitoring — given the locus-level evidence for T2D risk, periodic fasting glucose and HbA1c checks are prudent, especially as a complement to rs7903146 and rs12255372 results.

Interactions

This variant co-localizes with rs7903146 and rs12255372 in the TCF7L2 regulatory haplotype block. Carriers of C at rs290475 who also carry T at rs7903146 represent a subset with potential additive or independent effects on TCF7L2 expression levels in pancreatic islets and liver. Future fine-mapping studies at this locus may resolve whether rs290475 tags an independent causal variant or is in partial LD with the primary signal.